Generation of autologous cell sources holds a great promise in cell-based therapy for various diseases. Although therapeutic cell sources can be differentiated from induced pluripotent stem cells (iPSCs), their applications are restricted for clinical purposes due to tumorigenicity in vivo. SuPine Therapeutics has developed direct conversion technology to solve this limitation. Direct conversion is a technology to generate target cells from somatic cells(e.g. skin cells) bypassing the pluripotent stage thereby avoiding the risk of tumorigenicity. Our technology enables the generation of various cell types; iOPCs, iMNs, iHepSCs, iVPCs and iMoPs from somatic cells.